Expanded Access for Repotrectinib
NCT05926232
·
clinicaltrials.gov ↗
AVAILABLE
Status
INDUSTRY
Sponsor class
Interventions
DRUG:
Repotrectinib
Sponsor
Bristol-Myers Squibb